GoodRx Strengthens Core Business With New Initiatives, Analyst Upgrades On Potential Opportunities

Zinger Key Points
  • RBC writes that the company has a clear path to achieving a mid-teens+ annual EBITDA growth rate over the next three years.
  • Integrated Savings Program, direct contracting initiatives, and manufacturing solutions business, offer growth opportunities.

RBC Capital Markets issued an upgrade for GoodRx Holdings Inc GDRX shares.

The analyst stated the Integrated Savings Program (ISP) and direct contracting (DC) initiatives, along with the expansion of its manufacturing solutions business, offered significant new growth opportunities and strengthened the stability of its core Rx transaction business.

Related: Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024.

“We think this ‘hybrid’ approach presents both some incremental revenue opportunity while also better insulating GDRX from PBM-retailer disruptions like what happened with Kroger in mid-2022,” RBC wrote.

GoodRx announced a new direct contracting agreement with Kroger Co. KR earlier this month.

As a result of the agreement, patients will be able to present a GoodRx coupon at Kroger Pharmacies to receive more savings on the expected patient price for most generics, beginning on June 1.

With the initial selling and contracting largely completed — GoodRx has secured agreements with five pharmacy benefit managers (PBMs) and seven of the top 10 pharmacies, RBC writes the company has a clear path to achieving a mid-teens+ annual EBITDA growth rate over the next three years.

The analyst noted this plan would help adjust the current 10x ’25 EBITDA valuation to better reflect its growth rate and align it with the 14x peer average.

RBC has raised the price target from $8 to $10 and upgraded the stock from Sector Perform to Outperform.

Read Next: Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Says.

GDRX Price Action: GoodRX Holdings shares are up 2.92% at $7.41 at publication on Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsUpgradesHealth CarePrice TargetAnalyst RatingsGeneralBriefsExpert IdeasPharmaciespharmacyStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!